^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
76P - Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
Published date:
09/13/2021
Excerpt:
The efficacy population included 245 pts, 103 (85 TMB-H) in A1 and 142 (9 TMB-H) in A2....TMB-H status was more frequent in the dMMR pts, which is in line with known characteristics of these biomarkers.
Trial ID:
Test:
